Clinical Trial Update: Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 evaluation of the radiotracer [123I] AV151 for SPECT imaging in Alzheimer's disease subjects compared to healthy controls; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [123I] AV151 (AV151)

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Alzheimer Disease | Phase 1 | Status: TERMINATED